These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 22438253)
41. Disturbed CD4+ T cell homeostasis and in vitro HIV-1 susceptibility in transgenic mice expressing T cell line-tropic HIV-1 receptors. Sawada S; Gowrishankar K; Kitamura R; Suzuki M; Suzuki G; Tahara S; Koito A J Exp Med; 1998 May; 187(9):1439-49. PubMed ID: 9565636 [TBL] [Abstract][Full Text] [Related]
42. The loss of Gnai2 and Gnai3 in B cells eliminates B lymphocyte compartments and leads to a hyper-IgM like syndrome. Hwang IY; Park C; Luong T; Harrison KA; Birnbaumer L; Kehrl JH PLoS One; 2013; 8(8):e72596. PubMed ID: 23977324 [TBL] [Abstract][Full Text] [Related]
43. Low-level Cxcr4-haploinsufficient HSC engraftment is sufficient to correct leukopenia in WHIM syndrome mice. Gao JL; Owusu-Ansah A; Paun A; Beacht K; Yim E; Siwicki M; Yang A; Liu Q; McDermott DH; Murphy PM JCI Insight; 2019 Dec; 4(24):. PubMed ID: 31687976 [TBL] [Abstract][Full Text] [Related]
44. CXCL12 Mediates Aberrant Costimulation of B Lymphocytes in Warts, Hypogammaglobulinemia, Infections, Myelokathexis Immunodeficiency. Roselli G; Martini E; Lougaris V; Badolato R; Viola A; Kallikourdis M Front Immunol; 2017; 8():1068. PubMed ID: 28928741 [TBL] [Abstract][Full Text] [Related]
45. [CXCR4, a therapeutic target in rare immunodeficiencies?]. Bignon A; Biajoux V; Bouchet-Delbos L; Emilie D; Lortholary O; Balabanian K Med Sci (Paris); 2011 Apr; 27(4):391-7. PubMed ID: 21524404 [TBL] [Abstract][Full Text] [Related]
46. Activation of pertussis toxin-sensitive CXCL12 (SDF-1) receptors mediates transendothelial migration of T lymphocytes across lymph node high endothelial cells. Phillips R; Ager A Eur J Immunol; 2002 Mar; 32(3):837-47. PubMed ID: 11870628 [TBL] [Abstract][Full Text] [Related]
51. CXCR4 signaling in health and disease. Pozzobon T; Goldoni G; Viola A; Molon B Immunol Lett; 2016 Sep; 177():6-15. PubMed ID: 27363619 [TBL] [Abstract][Full Text] [Related]
52. The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. Nie Y; Waite J; Brewer F; Sunshine MJ; Littman DR; Zou YR J Exp Med; 2004 Nov; 200(9):1145-56. PubMed ID: 15520246 [TBL] [Abstract][Full Text] [Related]
53. WHIM Syndrome: from Pathogenesis Towards Personalized Medicine and Cure. Heusinkveld LE; Majumdar S; Gao JL; McDermott DH; Murphy PM J Clin Immunol; 2019 Aug; 39(6):532-556. PubMed ID: 31313072 [TBL] [Abstract][Full Text] [Related]
54. Plerixafor for the Treatment of WHIM Syndrome. McDermott DH; Pastrana DV; Calvo KR; Pittaluga S; Velez D; Cho E; Liu Q; Trout HH; Neves JF; Gardner PJ; Bianchi DA; Blair EA; Landon EM; Silva SL; Buck CB; Murphy PM N Engl J Med; 2019 Jan; 380(2):163-170. PubMed ID: 30625055 [TBL] [Abstract][Full Text] [Related]
55. Inhibitors of CXC chemokine receptor type 4: putative therapeutic approaches in inflammatory diseases. Hummel S; Van Aken H; Zarbock A Curr Opin Hematol; 2014 Jan; 21(1):29-36. PubMed ID: 24275689 [TBL] [Abstract][Full Text] [Related]